Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit funct...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2021-10-01
|
| coleção: | npj Breast Cancer |
| Acesso em linha: | https://doi.org/10.1038/s41523-021-00337-2 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
